Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Features

Features Pharma and Self-Perception: Knights, Knaves or Pawns?

Pharma and Self-Perception: Knights, Knaves or Pawns?

Even the industry's sunniest personalities don't deny that pharma has an image problem among outside constituencies, with an unfortunately high percentage of observers believing the biz is first and foremost about profits. Sachin Jain dives deep on this and other perceptions—accurate and otherwise—about the industry and its marketing machinery

Features

Partner Forum: Social for HCPs—Is Now the Time?

The increasing use of social media to reach consumers in the healthcare arena raises questions: Is it time to leverage it for HCPs, and if so, what are the most viable platforms for pharma-HCP communications?

Features Private View: Elliott Smith

Private View: Elliott Smith

Features EHR Update: Record Correction

EHR Update: Record Correction

Of all the channels through which brands can connect with HCPs, electronic health records have long been considered the most stubbornly and frustratingly impenetrable. Might advances in analytics and cloud technology, among other recent innovations, help simplify the EHR equation? Sarah Mahoney investigates

Features Loyalty Programs: Beyond the Co-Pay Card

Loyalty Programs: Beyond the Co-Pay Card

In the past, when pharma companies talked about patient-loyalty programs, what they were really talking about were the financial incentives underpinning them. But in the wake of Novo Nordisk's successful support program for diabetics, Cornerstones4Care, such initiatives are finally set to evolve. James Chase reports on the shifting focus of patient support

Features FDA Policy: Is Off-Label on the Table?

FDA Policy: Is Off-Label on the Table?

In years past pharma marketers had to check themselves before conveying off-label product claims, even though those off-label uses had long since become standards of care. But in recent months the FDA has signaled a willingness to open the off-label information floodgates. Former FDA Associate Commissioner Peter Pitts explains exactly why this matters

Features 2015 Top 20 Companies: Shire

2015 Top 20 Companies: Shire

Features 2015 Top 20 Companies: Biogen

2015 Top 20 Companies: Biogen

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters